Authorisation no cure to cartel risks posed by pharmaceutical patent settlement agreements
29 August 2022
Failed authorisation application likely to create difficulties for pharmaceutical settlement agreements in Australia
Read on
pharmaceutical
Patently uncertain: developments in pay-for-delay agreements in Australia
11 June 2020
Pay-for-delay pharmaceutical agreements have attracted scrutiny from regulators in the US and EU and are at greater risk of Australian regulatory attention
Read on
A very modest win: Generic Health gets 2% cut to Bayer’s $25 million damages
8 November 2018
Last year, Bayer was awarded more than $25 million (plus interest and indemnity costs) against Generic Health in the first Federal Court award of damages for pharmaceutical patent infringement.
Read on
Digital health receives funding boost from Federal Government
26 July 2018
Australia’s digital health sector received a major boost in April this year when the Federal Government announced a $55 million cash injection to launch the new Digital Health Cooperative Research Centre (CRC) and its programs which will bring together a consortium of more than 60 health, medical technology and pharmaceutical companies, universities and research institutes operating across the health, aged care and disability sectors.
Read on
Drugs in the fast lane: provisional drug registration and other proposed changes to the Therapeutic Goods Act
7 September 2017
Following the Australian Government’s Response to the Review of Medicines and Medical Devices Regulation in 2016, the government recently released exposure drafts for a set of significant reforms to the Therapeutic Goods Act 1989 (Cth).
Read on
Off to a running start? Federal Court of Australia permits generic manufacturer to make PBS application before patent expiry
28 April 2017
Can a manufacturer apply for Pharmaceutical Benefits Scheme (PBS) approval for a generic drug before the patent has expired?
Read on
Update: Otsuka Successful in Stay Application: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2015] FCA 848
26 August 2015
Further to our post of 7 July 2015, the proceedings brought by Otsuka and Bristol Myers Squibb (the “exclusive licensee” of Otsuka’s patents for aripiprazole) against Generic Health have taken another turn.
Read on
WIPO program encourages research into neglected diseases
5 May 2014
A novel WIPO program brings IP owners and researchers together to facilitate scientific research into neglected diseases, with the aim of bringing royalty-free treatments to least developed countries.
Read on